Munziq ameliorates myocardial ischemia-reperfusion injury by inhibiting inflammation via regulating NF-κB pathway

Abstract Objective: The objective of this study was to investigate the cardioprotective effects of Munziq on abnormal body fluid myocardial ischemia reperfusion injury (MIRI) and its underlying mechanism. Methods: Normal rats and abnormal body fluid rats were pre-treated with Munziq, and MIRI models were established. Histopathological changes and myocardial ultrastructure changes were observed by HE staining and transmission electron microscopy. Serum CK-MB, cTn-T, ICAM-1 levels were detected by ELISA. The levels of IL-1β, IL-6 and TNF-α in serum and myocardial tissue were detected to observe the anti-inflammatory effect. The expression levels of NF-κB signaling pathway proteins NIK, IKKα, Pikα, and p65 were detected by western blot analysis. Results: Our results showed that myocardial injury in the ABF MIRI group was more severe compared to control MIRI group. Munziq pretreatment has the potential to mitigate the pathological changes induced by ischemia reperfusion injury and could protective Cardiac Function. protein levels of NF-κB pathway and down-stream effectors IL-1β, IL-6, TNF-α, were significantly up-regulated in MIRI group while down-regulated in Munziq group. Interestingly, there was more activation of the NFKB signaling pathway in the ABF MIRI group and higher levels of downstream inflammatory cytokines. Conclusions: Our results suggest that MIRI was more serious in ABF. Munziq has cardioprotective effects in ischemia and reperfusion injury in both. This protective effect may be acted through suppressing the NF-κB signaling pathway.